Dermal Cell News Volume 5.05 | Feb 11 2019

TOP STORY

UCI-Led Study Reveals How Blood Cells Help Wounds Heal Scar-Free

New insights on circumventing a key obstacle on the road to anti-scarring treatment have been published by Maksim Plikus, an associate professor in developmental and cell biology at the University of California, Irvine School of Biological Sciences and colleagues. The research team discovered that the natural scar-free skin repair process relies partially on assistance from circulating blood cells. [Press release from EurekAlert! discussing online prepublication in Nature Communications] Press Release | Full Article

(Ranked by impact factor of the journal)

DERMAL STEM CELLS & TISSUE REGENERATION

Mature Vessel Networks in Engineered Tissue Promote Graft-Host Anastomosis and Prevent Graft Thrombosis

Researchers aimed to determine whether in vitro vessel maturation in transplantable grafts could accelerate vascular integration and graft perfusion and prevent thrombotic events in the grafts. To this end, endothelial cells and fibroblasts were cocultured on 3D scaffolds for 1, 7, or 14 days to form vasculature with different maturation degrees. [Proc Natl Acad Sci USA] Abstract

Pasireotide Protects Mammalian Cochlear Hair Cells from Gentamicin Ototoxicity by Activating the PI3K-Akt Pathway

Investigators demonstrated active caspase signal in organ of Corti explants exposed to gentamicin and showed that pasireotide treatment activated survival genes, reduced caspase signal, and increased hair cell survival. [Cell Death Dis] Full Article

GPER Activation Protects against Epithelial Barrier Disruption by Staphylococcus aureus α-Toxin

In vitro, G-1 reduced surface expression of the α-hemolysin (Hla) receptor, ADAM10, in a human keratinocyte cell line and increased resistance to Hla-mediated permeability barrier disruption. [Sci Rep] Full Article

Evaluation of the In Vitro Wound-Healing Activity of Calabrian Honeys

Researchers highlighted the renewed wound healing activity of honey, a viscous aromatic and sweet food, by way of in vitro wound-healing assays, using the HaCaT cell line. [Antioxidants] Full Article | Graphical Abstract

SKIN CANCERS & DISORDERS

Fibulin-3 Has Anti-Tumorigenic Activities in Cutaneous Squamous Cell Carcinoma

In vitro, knockdown of fibulin-3 in cutaneous squamous cell carcinoma cell lines A431 and SCL-1 cells promoted cell proliferation, protected cells against apoptosis and enhanced the migration and invasion abilities. [J Invest Dermatol] Abstract

The NLRP1 Inflammasome Pathway Is Silenced in Cutaneous Squamous Cell Carcinoma

Investigators assessed mRNA and protein levels in human primary keratinocytes and skin carcinoma-derived squamous cell carcinoma cell lines and detected a strong downregulation of expression of NLRP1 inflammasome components, as well as reduced expression of the pro-inflammatory cytokines proIL-1β and proIL-1α. [J Invest Dermatol] Abstract

Flavones Hydroxylated at 5, 7, 3′ and 4′ Ameliorate Skin Fibrosis via Inhibiting Activin Receptor-Like Kinase 5 Kinase Activity

The authors revealed that luteolin, quercetin, and myricetin selectively downregulated the phosphorylation of Smad2/3 in TGF-β/Smads signaling via binding to activin receptor-like kinase 5 and impairing its catalytic activity. [Cell Death Dis] Full Article

MITF Has a Central Role in Regulating Starvation-Induced Autophagy in Melanoma

In metastatic melanoma tumors and cell lines, MITF positively correlated with the expression of lysosomal and autophagosomal genes, which, interestingly, were different from the lysosomal and autophagosomal genes correlated with TFEB and TFE3. [Sci Rep] Full Article

Bixin, an Apocarotenoid Isolated from Bixa orellana L., Sensitizes Human Melanoma Cells to Dacarbazine-Induced Apoptosis through ROS-Mediated Cytotoxicity

Bixin promoted growth inhibition, reduced cell migration, induced apoptosis and cell cycle arrest in the G2/M phase. When associated with dacarbazine, bixin restored the sensitivity of A2058-cells to chemotherapy, enhancing its antiproliferative, anti-migratory and pro-apoptotic effects. [Food Chem Toxicol] Abstract | Graphical Abstract

Cirsiliol Suppressed Epithelial to Mesenchymal Transition in B16F10 Malignant Melanoma Cells through Alteration of the PI3K/Akt/NF-κB Signaling Pathway

Cirsiliol was found to be effective in restraining the colony formation and migration of fibronectin-induced B16F10 metastatic melanoma cells. Cirsiliol inhibited the activity and expression of matrix metalloproteinase-9. [Int J Mol Sci] Full Article | Graphical Abstract

Subscribe to one of our other 19 science newsletters such as Extracellular Matrix News & Cancer Stem Cell News.

Immune Therapy of Melanoma: Overview of Therapeutic Vaccines

The authors present the recent progressions in the melanoma immunotherapy, especially dendritic cells mRNA vaccines by reviewing recent literature. [J Cell Physiol] Abstract

Visit our reviews page to see a complete list of reviews in the dermal cell research field.

SpinalCyte Announces New Canadian Patent

SpinalCyte, LLC, announced the issuance of a new patent in Canada. The patent adds to the company’s intellectual property portfolio with 37 US and international patents issued with 100+ patents pending focused on fibroblast technologies. [SpinalCyte, LLC (PR Newswire Association LLC)] Press Release

Incyte Announces US FDA Has Extended the Review Period for Ruxolitinib (Jakafi^®) in Acute Graft-versus-Host Disease

Incyte announced that the FDA has extended the review period for the supplemental new drug application for ruxolitinib for the treatment of patients with acute graft-versus-host disease who have had an inadequate response to corticosteroids. The new prescription drug user fee act target action date is May 24, 2019. [Incyte Corporation] Press Release

Immunomic Therapeutics Licenses Investigational Canine Dermatitis Therapy to ZENOAQ

Immunomic Therapeutics, Inc. announced that the company has granted Japanese animal health company, ZENOAQ an exclusive license to develop and commercialize its investigational DNA vaccine, ITI-002, for canine atopic dermatitis and other companion animal allergies. [Immunomic Therapeutics, Inc.] Press Release

Exicure Announces US Clinical Sites for Phase Ib/II Oncology Trial

Exicure, Inc. announced four of the clinical trial sites for the Company’s Phase Ib/II trial of AST-008. [Exicure, Inc.] Press Release

Europe’s Next €1-Billion Science Projects: Six Teams Make It to Final Round

The European Commission has selected six research projects – in areas from health and energy to artificial intelligence and cultural heritage – to compete to become one of its next billion-euro ‘flagship’ science initiatives, Nature has learned. [Nature News] Editorial

France Set to Get First National Strategy for Research

France is preparing to implement a national, multi-year research plan for the first time – a move warmly welcomed by the heads of the country’s major research agencies. [Nature News] Editorial

Ukraine’s Science Revolution Stumbles Five Years On

Ukraine’s science system is in a precarious state, despite promised improvements in the wake of a revolution five years ago that aligned the country with the European Union. [Nature News] Editorial

NEW European CanCer Organisation (ECCO) 2019: European Cancer Summit
September 12-14, 2019
Brussels, Belgium

Visit our events page to see a complete list of events in the community.

NEW Professorship – Experimental Dermato-Oncology (Ludwig-Maximilians-Universität)

PhD Student Position – Immune Cell Communication (Universitätsmedizin Göttingen)

Postdoctoral Researcher – Skin Biology (Skin Science Foundation)

Research Fellowship – Cancer Biology (University of Dundee)

PhD Student – Cancer Research (Luxembourg Institute of Health)

Postdoctoral Fellowship – Inner Ear Regeneration (Sunnybrook Research Institute)

Postdoctoral Associate – Pathology (Stony Brook University)

Research Fellow – Stem Cell Biology (Brigham & Women’s Hospital)

Postdoctoral Position – Pluripotent Stem Cells (I-STEM)

Assistant Professor – Cancer Biology (University of Pennsylvania)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Dermal Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.